Search Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupAnemias, CytopeniasHemolytic DiseasesDiseaseParoxysmal Nocturnal HemoglobinuriaSubgroupICD10D59.5MeSHHemoglobinuria, ParoxysmalSequenceChemotherapyChemo-substanceDanicopanPegcetacoplanRavulizumabChemo-substanceDanicopanPegcetacoplanRavulizumabChemo-substanceDanicopanPegcetacoplanRavulizumabChemo-substanceDanicopanPegcetacoplanRavulizumabNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDanicopanEculizumabIptacopanRavulizumabSupportive substanceBalanced Crystalloid SolutionDanicopanEculizumabIptacopanRavulizumabSupportive substanceBalanced Crystalloid SolutionDanicopanEculizumabIptacopanRavulizumabSupportive substanceBalanced Crystalloid SolutionDanicopanEculizumabIptacopanRavulizumabNo. Substances123Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseInductionMaintenanceTherapy intentiondisease controlpalliativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlArthalgiaAstheniaConstipationDiarrheaFatigueHeadacheHematotoxicityIncrease AminotransferasesInfectionsNasopharyngitisNauseaNeutropeniaPainPyrexiaRashThrombocytopenia below 50 000/µlUpper Respiratory Tract InfectionVomiting only studiesPublicationAuthorHillmen PLee JLee J / Kulasekararaj APeffault de Latour R Diseasemind. 4 vorangegeangene Transfusionen in den letzten 12 Monaten, mind. 10% PNH Zellen und 100.000 Thrombozyten/µlmind. 4 vorangegegangene Transfusionen in den letzten 12 Monaten, mind. 10% PNH Zellen und 100.000 Thrombozyten/µlPNH, Erst-oder Zweitlinie nach EculizumabPNH, Klongröße mind 10%, Hämoglobinwert unter 10 g/dlPNH mit extravasaler Hämolyse, Patienten mindestens 6 Monate unter EculizumabPNH mit Hämoglobin < 10,5g/dl während 3 Monaten EculizumabOrigin301/302 studyBexley Wing, St. James’s University Hospital, Leeds, United Kingdom, Pegasus trialLeeds General Infirmary, Leeds, United Kingdom, TRIUMPHSeoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, ALPHA, ALXN2040-PNH-301Universite de Paris, Saint-Louis Hospital, Paris, France, APPOINT-PNH trialProtocols in Revision 8 protocols foundProtocols under revision.Eculizumab 600, Paroxysmal Nocturnal Hemoglobinuria, Induction (PID791)Eculizumab 900 / Danicopan 150, Paroxysmal Nocturnal Hemoglobinuria (PID2665)Eculizumab 900, Paroxysmal Nocturnal Hemoglobinuria, maintenance (PID792)Iptacopan 200, Paroxysmal Nocturnal Hemoglobinuria (PID2669)Pegcetacoplan 1080, Paroxysmal Nocturnal Hemoglobinuria (PID1928)Ravulizumab 2700, Paroxysmal Nocturnal Hemoglobinuria, Induction (PID1449)Ravulizumab 3300 / Danicopan 150, Paroxysmal Nocturnal Hemoglobinuria (PID2701)Ravulizumab 3300, Paroxysmal Nocturnal Hemoglobinuria, maintenance (PID1450)
